Innealta Capital LLC Sells 9,663 Shares of Elanco Animal Health Incorporated $ELAN

Innealta Capital LLC trimmed its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 49.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,016 shares of the company’s stock after selling 9,663 shares during the quarter. Innealta Capital LLC’s holdings in Elanco Animal Health were worth $143,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allworth Financial LP raised its holdings in shares of Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock worth $25,000 after acquiring an additional 2,090 shares in the last quarter. First Horizon Advisors Inc. raised its stake in Elanco Animal Health by 184.3% during the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after purchasing an additional 2,414 shares in the last quarter. Wealthquest Corp bought a new position in Elanco Animal Health during the first quarter valued at $56,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Elanco Animal Health by 261.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock worth $58,000 after buying an additional 2,922 shares in the last quarter. Finally, Covestor Ltd increased its holdings in shares of Elanco Animal Health by 510.9% in the 1st quarter. Covestor Ltd now owns 7,087 shares of the company’s stock worth $74,000 after buying an additional 5,927 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Down 0.6%

Shares of NYSE:ELAN opened at $21.48 on Friday. The company has a 50 day moving average of $20.11 and a 200-day moving average of $16.07. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The firm has a market cap of $10.67 billion, a P/E ratio of 358.06, a P/E/G ratio of 3.30 and a beta of 1.71. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $22.98.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.51% and a net margin of 0.78%.The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.09 billion. During the same period last year, the company posted $0.13 EPS. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the subject of several research analyst reports. Leerink Partnrs upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Piper Sandler lifted their price objective on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. UBS Group raised their target price on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Thursday. Zacks Research upgraded Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Friday, October 3rd. Finally, Stifel Nicolaus raised their price objective on Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.